CNTB Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Connect Biopharma Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.05 |
| 52 Week High | US$2.66 |
| 52 Week Low | US$0.68 |
| Beta | -0.31 |
| 11 Month Change | -13.22% |
| 3 Month Change | 3.96% |
| 1 Year Change | -15.32% |
| 33 Year Change | -76.92% |
| 5 Year Change | n/a |
| Change since IPO | -94.32% |
Recent News & Updates
Connect Biopharma Holdings (NASDAQ:CNTB) Is In A Strong Position To Grow Its Business
Sep 27
Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Are In A Position To Invest In Growth
Mar 07Recent updates
Connect Biopharma Holdings (NASDAQ:CNTB) Is In A Strong Position To Grow Its Business
Sep 27Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Are In A Position To Invest In Growth
Mar 07Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth?
Sep 19Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?
Mar 29Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Deliver On Growth Plans?
Dec 14Market Appears To Relegate Connect Biopharma To A Long-Term Hold
Oct 10Connect Biopharma Is A Sleeper Heading Into October Data Readout
Sep 26Connect Biopharma reports 1H results
Sep 13We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Aug 12We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Apr 29Connect Biopharma's Latest Dermatitis Drug Update Fails To Pump Up Shares
Jan 12We're Hopeful That Connect Biopharma Holdings (NASDAQ:CNTB) Will Use Its Cash Wisely
Jan 01Shareholder Returns
| CNTB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.5% | -7.5% | -1.2% |
| 1Y | -15.3% | 14.1% | 30.4% |
Return vs Industry: CNTB underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: CNTB underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| CNTB volatility | |
|---|---|
| CNTB Average Weekly Movement | 16.1% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CNTB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CNTB's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 81 | Barry Quart | www.connectbiopharm.com |
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn’s disease.
Connect Biopharma Holdings Limited Fundamentals Summary
| CNTB fundamental statistics | |
|---|---|
| Market cap | US$53.87m |
| Earnings (TTM) | -US$21.38m |
| Revenue (TTM) | US$24.12m |
2.4x
P/S Ratio-2.7x
P/E RatioIs CNTB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNTB income statement (TTM) | |
|---|---|
| Revenue | US$24.12m |
| Cost of Revenue | US$0 |
| Gross Profit | US$24.12m |
| Other Expenses | US$45.50m |
| Earnings | -US$21.38m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 100.00% |
| Net Profit Margin | -88.65% |
| Debt/Equity Ratio | 0% |
How did CNTB perform over the long term?
See historical performance and comparison